top of page

Search this site

201 results found with an empty search

  • Q2 2026 Behavioral Health M&A Report

    Behavioral Health M&A By Kevin Taggart, CM&AP, Managing Partner, Mertz Taggart Published August 2026. Transaction data reflects deals closed between April 1 and June 30, 2026, as tracked by Mertz Taggart - Q3 2026 Behavioral Health M&A Report is now available At a Glance Behavioral health M&A slowed in Q2 2026. A total of 27 transactions closed during the quarter — 21 traditional M&A deals and 6 growth deals — making it the lightest quarter for closed traditional volume in the Mertz Taggart data set going back to 2022. Mental health led all sub-sectors with 14 closed deals, followed by autism and I/DD with 6 and addiction treatment with 2. Two new private equity platforms formed, nonprofit and health-system combinations accounted for roughly a third of closed traditional volume, and several of the quarter's largest transactions were announced rather than closed. A total of 27 closed transactions — 21 traditional M&A deals and 6 growth deals — were reported in Q2 2026. Traditional M&A volume declined from 34 closed deals in Q1 2026 and 29 in Q2 2025, making it the lightest quarter for closed behavioral health M&A in our data set going back to 2022. The six growth deals carried a combined disc`losed value of approximately $183.8 million across the six rounds with disclosed terms. Note: Total industry transactions do not necessarily equal the sum of the sub-industries, as many transactions include more than one sub-industry. "Volume was down, but the composition of the quarter is more interesting than the count. Two new private equity platforms formed, one of the largest nonprofit combinations we've seen in years closed, and the sponsor-backed strategics that have driven this market for three years kept buying — just in smaller bites. What we're not seeing is the mid-size auction. Buyers are there; sellers of scale largely sat out the quarter." — Mertz Taggart Managing Partner Kevin Taggart said. Why nonprofit combinations stood out Nonprofit and health-system combinations were unusually prominent, accounting for roughly a third of closed traditional volume. Several were driven by Medicaid economics, with acquired organizations citing scale as the path to absorbing reimbursement shortfalls. It is one quarter, not a trend, but worth watching as state budgets tighten. "Anyone underwriting behavioral health right now is underwriting Medicaid more cautiously than in years past, but we expect this to pass as things eventually quiet down in DC. Buyers with capital are being deliberate — paying up for clean, in-network, growing businesses and being more diligent on everything else. For an owner, that spread is the whole story." — Taggart said. → Related: What Behavioral Health Owners Should Understand Before Comparing Offers Addiction Treatment M&A Two addiction treatment deals closed in Q2 2026, down from 6 in Q1 2026 and 7 in Q2 2025, and the lowest quarterly total in our data set. Substance use disorder deal flow has trailed its 2022 pace for several consecutive quarters as platforms work through integration, payer contracting and, in a few cases, balance sheet repair. MKH Capital Partners forms a new platform with Haven Health Management The most significant addiction treatment transaction of the quarter was MKH Capital Partners' platform acquisition of Haven Health Management, a Palm Springs, Florida-based operator of 22 Joint Commission-accredited mental health and substance use treatment locations across nine states and Puerto Rico with nearly 2,000 employees. Brands include Indiana Center for Recovery, The Haven Detox and The Recovery Team. Terms were undisclosed but described as nine figures. MKH concurrently acquired United Billing Solutions to support in-network billing across Haven's brands, and named Brian Thorn chief executive officer. Advantage Behavioral Health highlights A sizable behavioral health transaction was also announced (not closed) during the quarter: Advantage Behavioral Health agreed to be acquired by QCF/I, Inc. in a transaction financed through a planned $610 million non-rated municipal bond issuance, although the deal had not closed as of quarter-end. Clearview Capital, Advantage’s founders and management were expected to receive approximately $415 million at closing, with the potential for an additional $100 million tied to performance milestones. We classified the transaction within mental health because mental health is Advantage’s primary line of business, although the company also provides substance use disorder services. The announcement is another positive signal that investors remain interested in scaled SUD platforms. Also in the quarter, Abacus Investments-backed Recover Now closed its merger with Widespread Wellness, a Tennessee-based outpatient provider. “Two closings is a low number, and I don’t want to over-read it. SUD is where the gap between good assets and everything else is widest right now. Platforms are still looking, but they’re selective on payer mix and length of stay, and some are still cleaning up what they bought in 2021 and 2022. For a quality operator, there’s very little competing supply. It was also encouraging to see a transaction like Haven close and Advantage Behavioral Health get announced, largely because of the scale of both businesses,” Taggart said. Mental Health M&A Fourteen mental health deals closed in Q2 2026, down from 18 in Q1 2026 and 20 in Q2 2025. The sub-sector continues to account for the majority of behavioral health transaction volume, with activity split between technology-enabled platforms consolidating and a steady base of outpatient psychiatry and community provider combinations. The quarter's largest mental health transactions PsychPlus acquired Koa Health, a multinational digital mental health company, in a combination the buyer describes as the largest technology-enabled mental health platform globally, serving more than six million patients across the U.S., Europe, Australia and Asia-Pacific. PsychPlus operates more than 200 U.S. locations; Koa founder Dr. Oliver Harrison becomes president of PsychPlus. Spring Health closed its acquisition of Alma, the mental health provider marketplace, materially expanding Spring Health's in-network provider supply. The deal was announced in Q1 and closed May 1st. WPS Health Insurance acquired Mavida Health, a women's mental health platform — one of the quarter's few payer-side acquisitions of a virtual provider. Other closed mental health transactions: Thurston Group-backed Arc Health acquired North Carolina Mental Health & Psychiatry Group. Hillandale Advisors-backed Sidekick Therapy Partners acquired Word of Mouth Clinical Associates, a Tennessee pediatric therapy practice. Curio Digital Therapeutics acquired the Nora Mental Health franchise system, adding a national outpatient footprint to its digital platform. Unyte Health acquired Vital Links and Vital Sounds, the developers of Therapeutic Listening. Sweetser acquired Common Ties Mental Health, and Keystone Human Services merged with Mikayla's Voice — both nonprofit combinations. UConn Health assumed operation of the state-run Albert J. Solnit Children's Center in Middletown, Connecticut; Neosho Memorial Regional Medical Center acquired Kansas-based Ashley Clinic; and Xpress Wellness Urgent Care acquired Wichita's Midwest Counseling Services. Mental health deals highlights Several larger mental health transactions were announced but had not closed at quarter end. Clearview Capital agreed to exit Advantage Behavioral Health, a New Jersey-based operator of more than 30 mental health and sober-living facilities in eight states, to nonprofit QCF/I, Inc., financed by a planned $610 million non-rated municipal bond issuance. Clearview and ABH's founders and management are expected to receive roughly $415 million at closing, with up to $100 million more tied to milestones. ABH is projected to generate approximately $170 million of revenue and $78 million of EBITDA this year. Mental health growth capital in Q2 2026 HPS Investment Partners agreed to take majority ownership of Discovery Behavioral Health in exchange for a substantial debt reduction, subject to regulatory approval. Universal Health Services' $835 million acquisition of Talkspace was approved by shareholders May 30 and is expected to close in Q3 2026. On the growth side, mental health accounted for all six of the quarter's rounds. Click Therapeutics raised $50 million in a Series D from Boehringer Ingelheim to commercialize CT-155, a prescription digital therapeutic for schizophrenia symptoms. Tava Health raised a $40 million Series C led by Centana Growth Partners; Instride Health raised $30 million from Echo Health Ventures; Klinic raised $24 million; Zocalo Health raised $22.8 million from EO Ventures; and Vanna Health raised $17 million from Health Velocity Capital. Autism and Intellectual/Developmental Disabilities M&A Six autism and I/DD deals closed in Q2 2026, down from 10 in Q1 2026 and roughly in line with the 7 closed in Q2 2025. New platform formation and nonprofit consolidation drove the quarter. Merakey and I Am Boundless: the quarter's largest behavioral health transaction The largest transaction of the quarter in any behavioral health sub-sector was Merakey's acquisition of I Am Boundless, an Ohio nonprofit serving people with intellectual and developmental disabilities and behavioral health needs. Merakey, a Pennsylvania-based nonprofit operating in 12 states, and Boundless will together generate up to $1 billion in annual revenue, with Boundless keeping its name and leadership. Boundless had grown revenue from $20 million to an expected $200 million through five acquisitions in seven years, and its CEO pointed to Medicaid shortfalls as the reason it sought a larger partner. Cathay Capital launches Ascendia Autism Care Cathay Capital launched Ascendia Autism Care, a new applied behavior analysis platform built around a founding affiliate operating 20 centers across eight states with more than 400 clinicians. Ascendia focuses on early intervention for children ages two to six and plans to grow through de novo expansion and additional clinical partnerships. Additional Q2 autism and I/DD transactions: Gryphon Investors-backed LEARN Behavioral acquired Little Leaves Behavioral Services from FullBloom. Frontline Healthcare Partners-backed JoyBridge Kids acquired A Bridge to Achievement, its first step into adult services. Doma acquired MPA Services, an Ohio I/DD provider. The founders of North Arrow ABA in Michigan converted the practice to 100% employee ownership. "ABA and I/DD are still where the most consistent buyer interest is, and Cathay's launch is a good example — a firm entering around a single high-quality founding group rather than buying a built rollup. The other story is the nonprofit side moving. Merakey and I am Boundless exists because the Medicaid math doesn't work at smaller scale according to I am Boundless, and I expect more of those combinations over the next 18 months." — Taggart said. → Related: How to Prepare Your Behavioral Health Business for Sale in 2026 If you are interested in downloading the PDF version of the Q2 2026 Behavioral Health M&A Report, click the download link below:

  • How the 2026 Election Affects Behavioral Health Valuations and M&A

    By Kevin Taggart, CM&AP, Managing Partner, Mertz Taggart How will the 2026 election affect behavioral health M&A? Our expectation is continued, selective acquisition activity—not an automatic increase in valuations. Divided government should make additional major Medicaid cuts harder to enact, but it does not reverse existing law or guarantee better reimbursement. For mental health, addiction treatment, autism, and I/DD owners, the practical effect depends on payer mix, state policy, staffing, and the durability of earnings. Democrats have won control of the House and Senate, with the new Congress taking office in January. President Trump remains in office. Holland & Knight’s pre-election analysis identified the resulting constraint: greater congressional leverage does not make a wholesale reversal of the administration’s healthcare agenda likely. For an owner considering a sale, the question is what changes the earnings a buyer can reasonably expect your business to generate—and the risks attached to collecting them. Here is our base case for the next 12–18 months. These are transaction judgments, not forecasts from a quantified election-to-valuation model. Medicaid: The election does not remove the implementation risk We expect a Democratic Congress to make another major legislative reduction in Medicaid funding less likely. We would not assume it will quickly reverse restrictions already enacted. For behavioral health, eligibility administration deserves particular attention. CMS’s June 2026 rule implements work requirements for certain adults in the Medicaid expansion population and specified waiver programs, generally beginning January 1, 2027. It is not a blanket requirement for all Medicaid patients; exemptions include certain disabled or medically frail individuals. The behavioral health exceptions require care. KFF’s analysis explains that the rule ties medical frailty to a person’s ability to meet the requirements, not simply the presence of a diagnosis. An owner should not assume every patient with a mental health condition or substance use disorder is automatically protected. Our concern is not that every affected patient stops needing treatment. It is that a patient may have difficulty establishing or maintaining coverage, disrupting treatment and payment. In a sale, we would examine your actual patient eligibility categories, state implementation, coverage interruptions, denials, and collections. A headline estimate of national coverage losses is not a revenue forecast for your business. Mental health: More parity attention does not guarantee higher collections We expect stronger congressional interest in behavioral health access and insurer practices. That should not be modeled as an immediate increase in reimbursement or a reduction in denials. Mental health parity law remains in place, but the enforcement picture is more complicated than “the new rules took effect.” The Department of Labor’s September 2026 guidance maintains nonenforcement of provisions newly added by the 2024 parity rule while recognizing continuing statutory obligations, including comparative-analysis requirements. Congressional pressure could influence the debate. It does not itself rewrite insurer contracts, settle litigation, or change an agency’s enforcement policy. There are also specific bipartisan advocates. Reps. Doris Matsui (D-CA) and August Pfluger (R-TX), with other colleagues, reintroduced the Ensuring Excellence in Mental Health Act in April. The proposal would establish more durable payment arrangements for Certified Community Behavioral Health Clinics, or CCBHCs. That matters, but it is a model-specific proposal—not a payment increase for every counseling or psychiatry practice. SAMHSA’s CCBHC requirements include comprehensive services, care coordination, and round-the-clock crisis availability. For a private practice owner, we would still focus on clinician retention, completed visits, contracted rates, authorization requirements, and cash collections. We would not increase the valuation merely because access has bipartisan support. Addiction treatment: Authorization is not the same as funding Addiction treatment already has evidence of bipartisan legislative support. Sen. Bill Cassidy (R-LA) helped advance the SUPPORT reauthorization, and Rep. Brett Guthrie (R-KY) sponsored the House legislation that became law on December 1, 2025. The election did not create that support. The distinction owners should watch is between authorizing a program and funding it. The Congressional Research Service’s September 2026 review states explicitly that the law does not appropriate funds. Renewed program authority is not, by itself, a grant award or dependable provider revenue. Our expectation is continued negotiation over prevention, treatment, recovery, and workforce programs. For a transaction, we would separate recurring reimbursement from grants and contracts with renewal, transfer, or funding risk. Marwood Group’s January 2026 public SUD market summary also distinguishes underlying treatment demand from reimbursement variability and financial sustainability. That is the right distinction for an owner: substantial need does not prove your particular program can deliver profitable, collectible care. We would assess the economics of your actual levels of care, payer relationships, staffing, and referral sources—not treat all addiction treatment businesses as interchangeable. Telehealth: Coverage and prescribing are different questions For virtual psychiatry and medication-based addiction treatment, we would not assume that supportive political statements resolve the operating rules. The DEA’s broad temporary controlled-medication prescribing extension runs through December 31, 2026. The DEA also identifies separate authorities for buprenorphine treatment and certain veterans’ care, each with its own requirements. That is not the same as a universal expiration of behavioral health telehealth. Whether a visit is covered, whether a clinician may practice across state lines, and whether a controlled medication may be prescribed remotely are separate questions. Our expectation is that buyers will want a defensible operating plan under the rules applicable to your business. Do not count on an unannounced extension, or assume a change in one authority shuts down every virtual service. Autism and I/DD: Do not combine different coverage risks Autism and ABA services For Medicaid-enrolled children under 21 entitled to Early and Periodic Screening, Diagnostic, and Treatment benefits, the federal EPSDT framework requires coverage of medically necessary services within the specified federal benefit categories. That framework is different from adult waiver-based services. It does not guarantee any provider a particular rate or every requested treatment hour. In its February 2026 public autism-sector summary, Marwood Group described increasing scrutiny of utilization, billing, reimbursement, and benefit administration, including at PE-backed platforms. We do not expect the election to eliminate those issues. For an ABA owner, the more useful valuation evidence is support for medical necessity, reliable documentation, delivered versus authorized hours, supervision, clinician capacity, and actual collection experience. I/DD community and residential supports For I/DD businesses, identify the funding authority for each service. Do not apply the children’s EPSDT framework to every adult residential, day, or community-support program. There are concrete advocates for expansion. Sens. Ben Ray Luján (D-NM) and Tim Kaine (D-VA) introduced the HCBS Access Act, proposing a mandatory Medicaid home- and community-based benefit, more funding, and workforce support. Rep. Debbie Dingell (D-MI) introduced the House version. That is a meaningful policy direction, not an enacted entitlement expansion. Our expectation is more attention to access and workforce capacity, but not an immediate national improvement in I/DD margins. State rates, available program capacity, staffing costs, and service obligations still need to support the earnings being sold. What does this mean for behavioral health valuations and sale timing? Our base case is continued buyer interest in businesses with sustainable earnings and a credible operating model, with greater caution where eligibility, reimbursement, staffing, or compliance remains unresolved. We would not promise an election-driven increase in multiples or a specific change in deal volume. For recent transaction context, see our Q3 2026 Behavioral Health M&A Report. The election is a change in the policy backdrop, not the starting point for the acquisition market. We would not accelerate a sale because Democrats won Congress, and we would not postpone one simply to wait for a more supportive political environment. Waiting can make sense if you can identify an achievable improvement that would materially strengthen value: stabilizing clinician capacity, implementing a signed rate increase, reducing denials, improving management depth, or resolving a documented compliance issue. The test is whether the expected benefit of waiting justifies the operating and personal risk—not whether Washington sounds more favorable to behavioral health. For preparation, read How to Prepare Your Behavioral Health Business for Sale in 2026. Frequently asked questions Will the election increase the value of my behavioral health business? Not automatically. Our view is that value improves when a change supports sustainable earnings, reduces buyer risk, or strengthens competition for your specific business. Political support alone does not establish any of those outcomes. Are patients with mental health conditions or addiction exempt from Medicaid work requirements? Some patients may qualify for exemptions, but a diagnosis alone should not be treated as a blanket exemption. The applicable eligibility category, functional limitations, verification requirements, and state implementation matter. Review the current rules rather than assume all behavioral health revenue is either protected or at risk. Does stronger mental health parity mean insurers must pay my requested rates? No. Do not translate support for parity into a guaranteed contract rate, approval of every requested service, or collection of every claim. For a sale, show how your actual payer contracts, authorizations, denials, and collections support the earnings presented. Considering a sale? If you want to understand how policy exposure, payer mix, or operating performance could affect your business’s value, contact Mertz Taggart for a confidential conversation. Kevin Taggart, CM&AP, is Managing Partner at Mertz Taggart. The firm advises owners on behavioral health M&A, including mental health, addiction treatment, autism, and I/DD services. Policy status reviewed November 4, 2026. Expectations about valuations and acquisition activity reflect Mertz Taggart’s judgment, not a guarantee of transaction outcomes.

  • How Healthcare Owners Can Prepare for Management Meetings

    By Cory Mertz, M&AMI, Managing Partner, Mertz Taggart At a Glance A management meeting helps healthcare sellers explain the business and evaluate prospective buyers before an LOI. Prepare to discuss financial results, management responsibilities, and known issues, with explanations consistent with the offering materials. Set confidentiality boundaries in advance, ask about the buyer’s plans, and organize follow-up around questions that still need supporting information. You have spent years getting to know your business. You understand why the team is organized the way it is, what has driven performance, and where the opportunities and challenges are. A prospective buyer comes to a management meeting with a much shorter history: the materials it has reviewed and the questions those materials have raised. The meeting gives you time to put that information in context. It also gives you a closer look at the people who may become the next owners of the business. Their understanding of the operation, their plans, and your agreed-upon role post-closing all matter as you decide whom to move forward with. Good preparation helps make the discussion useful for both sides, so you want to be comfortable explaining the business, clear about what can be shared, and ready to ask your own questions. Your advisor should help you prepare and work through the information needed afterward. Know what the meeting needs to accomplish In a process using indications of interest, buyers review the offering materials and submit an initial proposal, and selected buyers are then invited to management discussions before submitting an LOI. At that point, the seller is still evaluating alternatives and buyers are still competing for the opportunity. Buyers may ask for additional information ahead of the meeting so they can prepare. Work with your advisor to understand what they are asking for and why. Some requests will help the buyer develop a more informed LOI; others may involve information that should remain restricted at that stage. Before the LOI, we do not share employee names, referral-source names, or patient information. Establish those boundaries with your advisor in advance and route requests for those details back through the transaction team. You can still have a detailed discussion of the operation while protecting the people and relationships behind it. → Related: What Healthcare Owners Should Know Before Accepting an LOI Refresh your understanding of what the buyer has seen Before the meeting, review the offering materials and financial data book with your advisor. Know which periods are being presented, how the earnings calculation has been developed, and what assumptions are included in the forecast. Those materials are the buyer's starting point, so your explanations should be consistent with them. Think through material changes in performance and the operating decisions behind them. If results have changed since the materials were prepared, be ready to explain what happened. A buyer can follow the numbers more easily when you connect them to the way the business is being run. You may be asked something that requires more analysis or a checked figure, and it is reasonable to say you will follow up; identify what is needed and work with your advisor to provide a supported answer afterward. An answer that can be verified is more useful to the transaction than an estimate offered simply to keep the conversation moving. Known financial or compliance matters need the same preparation. Your transaction team should understand the issue before the meeting, including what has been done and what remains open. The appropriate specialist can help you prepare an accurate explanation. Be ready to explain how the team runs the business Buyers want to understand who makes decisions and how the operation would continue through a transition. Be clear about your own responsibilities and the work other leaders already manage. If selected executives are participating, each should be comfortable explaining the areas they actually lead. This is also where a buyer begins to form an impression of the company's culture. In a confidential sale, the buyer generally has limited access to the broader workforce. Much of what it learns comes through conversations with you and the management team involved in the process. Use the conversation to learn about the buyer Pay attention to the buyer's questions. Have they worked through the materials? Do they understand the operating issues in your sector? Can it explain what it still needs to confirm? Those observations help you assess how informed their next proposal is likely to be. Ask why your business interests the buyer and how it fits their plans — whether it already has an operation in the sector or is entering it for the first time — and enough detail to understand the reasoning behind the interest. Discuss your future role as well, since a buyer may be assuming you will remain involved longer than you intend. Learning that during management discussions gives you time to work through the difference before selecting an offer. Follow through on what the meeting reveals Afterward, take time with your advisor to review what you learned. Which questions were answered? What still needs support? Did the buyer's expectations fit your plans? Organize the follow-up so material assumptions can be addressed before the next proposal arrives. Key Takeaways Review the offering materials, financial data and assumptions before meeting buyers. Prepare clear explanations of management responsibilities and material changes in performance. Use the discussion to assess the buyer’s rationale, plans and expectations for your role. Route sensitive requests through your advisor and follow up with checked, supporting information. A management meeting can help you understand both the offer a buyer is preparing and the working relationship you may be entering. Preparing for that conversation gives you a better basis for choosing the next step. If you are approaching management discussions, we would be glad to talk confidentially about the questions that matter for your business and your transition. → Related: What Actually Happens During Healthcare M&A Due Diligence

  • How the 2026 Election Affects Home Health, Home Care, and Hospice Valuations

    By Cory Mertz, M&AMI, Managing Partner, Mertz Taggart · November 5, 2026 · At a Glance Democrats won control of the House and Senate, and the new Congress takes office in January. For home health, home care, and hospice owners, that may make additional major Medicaid cuts harder to enact, but it does not reverse existing law or raise agency valuations on its own. Reimbursement, staffing, sustainable earnings, and compliance still drive value. How will the 2026 election affect home-based care M&A? Our expectation is continued acquisition activity, not an automatic increase in agency valuations. Divided government should make additional major Medicaid cuts harder to enact, but it does not reverse existing law. For an owner considering a sale, reimbursement, staffing, sustainable earnings, and compliance remain more useful indicators of value than the election result alone. Democrats have won control of the House and Senate, setting up divided government when the new Congress takes office in January. President Trump remains in office. That limits how quickly, and how completely, healthcare policy can change. The practical question is whether anything changes the earnings a buyer can reasonably expect your agency to generate, the risks attached to those earnings, or the buyers willing to compete for your business. Our base case is less room for additional major Medicaid cuts, more healthcare oversight, and no automatic increase in home health, home care, or hospice valuations. That is our judgment, not a quantified forecast of election-driven changes in deal volume or EBITDA multiples. Will the election increase agency valuations? We would not assume an election-driven increase in EBITDA multiples. A more favorable policy outlook can improve confidence, but reduced concern about a future cut is not the same as an enacted reimbursement increase. Neither guarantees that your margins improve. A buyer might become more comfortable with your reimbursement outlook without changing its assessment of your staffing costs, referral concentration, or ability to grow. Our assessment differs by business model: Medicaid-funded home care: We would watch state funding decisions and reimbursement relative to caregiver wages. Medicare-certified home health: We would focus on agency-specific payment changes, payer contracts, and clinical productivity. Hospice: We would examine the durability of earnings and clinical, documentation, and reimbursement exposure. Private-pay home care: We would assess whether billing rates, caregiver compensation, and client retention support sustainable margins. For transaction context rather than an election forecast, see our Q3 2026 Home-Based Care M&A Report. How will the 2026 election affect Medicaid home care funding? Existing funding pressure does not disappear. Another major legislative reduction in Medicaid funding becomes less likely, but a rapid reversal of existing funding restrictions is a much weaker assumption. A Democratic Congress will have greater leverage over legislation, spending negotiations, and oversight. However, Holland & Knight’s pre-election analysis cautioned that outright repeal of provisions in the 2025 reconciliation law would be difficult. Targeted delays or additional implementation flexibility were more plausible avenues for change. BRG’s John Barkett made the constraint clear in comments reported by Fierce Healthcare on November 2: “President Trump will still be president, and he will view a policy that amends the One Big Beautiful Bill Act in favor of hospitals as a concession to Democrats—and therefore, he’ll be looking for something in return.” His comments concerned hospitals, not home care valuations. The relevant point for agency owners is the legislative constraint: a new congressional majority does not automatically reverse existing law. Home care also has an influential advocate in Sen. Ron Wyden (D-OR), currently the top Democrat on the Senate Finance Committee. His October home care initiative seeks to expand access and strengthen the workforce. With Democrats taking Senate control in January, we expect that agenda to receive greater attention. That improves the prospects for hearings and targeted negotiations, not a guarantee of new funding or higher agency margins. Exposure also remains state-specific. KFF’s October analysis of Medicaid home care noted that most services are optional for states to provide and could face pressure from reduced federal funding. Some states had cut programs, while others continued making enhancements. For your agency, we would focus on whether reimbursement can keep pace with caregiver compensation, whether authorized hours become delivered and billable hours, and how much of your earnings depends on a rate increase or program decision that may not be sustainable. Those answers are more useful in a valuation discussion than a national election headline. What does the election mean for home health reimbursement? CMS finalized the 2027 home health rule on November 4, 2026, estimating a 2.4% aggregate increase in Medicare payments over 2026. That is an industry-wide estimate, not a forecast for your agency. For what the final rule means for values, see 2027 Home Health Final Rule: What It Means for Agency Values and M&A. We would assess a sale using the final payment rule and your actual economics, rather than assuming congressional control will deliver a particular reimbursement result. There is bipartisan support for protecting home health access. Reps. Kevin Hern (R-OK) and Terri Sewell (D-AL) introduced the Home Health Stabilization Act in 2025 to pause payment reductions while a more sustainable system is developed. We see targeted reimbursement relief as a more plausible policy outcome than an election-driven valuation premium. But an owner should not count that relief as earnings until the applicable policy actually changes. The operating constraints predate this election. In its 2024 skilled home healthcare outlook, Marwood Group identified aging demographics as a demand driver while highlighting staffing shortages as a challenge to serving that demand. Our view is that favorable demand has limited transaction value if your agency cannot staff admissions profitably. Demonstrating referral conversion, clinician capacity, and payer-level profitability is more productive than waiting for a political benefit. How does the election affect hospice payments and oversight? It does not change them directly. Hospice’s fiscal 2027 Medicare payment update was established before the election. CMS set a 2.3% increase, effective October 1, 2026, subject to applicable adjustments and quality-reporting requirements. That rule also highlighted claims-based information intended to identify providers that may need additional education and oversight. The election did not create the payment update or remove the compliance focus. Hospice advocates are not proposing less oversight across the board. Sen. Mark Warner (D-VA) and Rep. Linda Sánchez (D-CA) introduced the Hospice CARE Act in March 2026 with proposed home respite benefits and payment reforms alongside stronger ownership transparency and more surveys. Our takeaway: support for the hospice benefit can mean expanded services and tighter accountability at the same time, not an automatic improvement in every operator’s economics. We do not expect the result to eliminate the investment case for a well-run hospice. Nor do we expect it to make unresolved compliance exposure easier to sell. Our approach would remain the same: establish sustainable earnings, examine patient eligibility and documentation, understand aggregate cap exposure, and resolve issues that could cause a buyer to question the business. Should private-pay home care owners count on labor-rule savings? Not as current earnings. Private-pay home care owners should separate federal reimbursement policy from their own business economics. Labor policy remains relevant. The Department of Labor has proposed restoring broader companionship and live-in domestic service exemptions. Its published guidance describes a proposal, not a blanket, finalized exemption for home care agencies. We would not count uncertain regulatory savings as current EBITDA. Even if an exemption becomes available, your agency still needs to recruit and retain caregivers, comply with applicable requirements, and maintain service quality. For a sale, distinguish demonstrated margins from potential upside dependent on a future policy change. Can home health and hospice acquisitions still close? Yes. The Medicare enrollment moratorium is not a blanket acquisition ban. CMS’s guidance allows enrolled providers to acquire or merge with other enrolled providers when the transaction does not require a new enrollment under applicable ownership-change rules and does not add new locations. Existing certified locations transferred through a qualifying transaction are not treated as new locations. CMS imposed the six-month nationwide moratorium beginning May 13, 2026, with the possibility of extensions. For your transaction, ownership history and enrollment requirements may matter more than the election result. Verify those facts early. Do not assume either that a sale is blocked or that an existing enrollment automatically commands a premium. Policy status as of November 2026 Policy Status Home health CY2027 payment rule Final, Nov. 4, 2026; est. +2.4% aggregate Hospice FY2027 payment update Final; +2.3%, effective Oct. 1, 2026 HH/hospice enrollment moratorium Six months from May 13, 2026; may be extended DOL companionship/live-in exemption Proposed, not final Home Health Stabilization Act Introduced 2025 Hospice CARE Act Introduced March 2026 Should you sell your agency now or wait? We would not change sale timing solely because of the election. Waiting can make sense when a specific, achievable improvement could materially strengthen earnings or reduce buyer risk. Examples include stabilizing staffing, demonstrating the benefit of an implemented rate increase, improving payer contracts, or resolving a compliance issue. Waiting for a broadly “better political environment” is a less defensible plan. It has no defined outcome or timetable. For a sale over the next 12–24 months, we would assess: What your agency can sustainably earn under applicable rules. Which buyers have a credible reason to acquire it. What could materially change earnings or buyer interest before a sale. Whether the expected benefit of waiting justifies the operating and personal risk. Our expectation is continued, selective acquisition activity, not an election-driven surge or a broad withdrawal of buyers. The useful response is to understand your agency’s specific exposure and make the decision around your business and your objectives. For more on preparation, read Selling a Home Health, Hospice, or Home Care Agency in 2026. Frequently asked questions Does a change in Congress automatically change Medicare reimbursement? No. A change in congressional control does not itself change your agency’s Medicare payment rates. Congress can change the law and oversee agencies, but payment outcomes depend on the applicable legislation and CMS rules. Do not model an election result as an enacted rate increase. Will Medicaid funding pressure affect private-pay home care the same way? Not directly. A private-pay agency’s revenue is not funded through Medicaid reimbursement. We would examine its actual payer mix, caregiver costs, and clients’ ability to afford services rather than apply a Medicaid funding assumption to the entire business. Does the election lift home health and hospice enrollment restrictions? No. The election itself does not lift CMS’s enrollment moratorium. Whether a transaction can proceed depends on the applicable requirements, including whether it requires a new enrollment. Check current CMS guidance and the agency’s ownership history before choosing a transaction structure. Key Takeaways An election result is not a rate increase. Payment changes come through legislation and CMS rules. Divided government may make new major Medicaid cuts harder to pass, but a quick reversal of existing funding restrictions should not be assumed. Medicaid exposure is state-specific, so watch your state’s funding decisions and how reimbursement compares to caregiver wages. Home health and hospice transactions can still close under the enrollment moratorium when they meet CMS ownership-change rules and add no new locations. Base sale timing on your agency’s earnings and buyer interest, not the political calendar. Considering a sale? If you want to understand how reimbursement, staffing, or policy exposure could affect your agency’s value, contact Mertz Taggart for a confidential conversation. Cory Mertz, M&AMI, is Managing Partner at Mertz Taggart, where he advises home health, home care, and hospice owners on selling their businesses. Policy status reviewed November 6, 2026. Expectations about valuations and acquisition activity reflect Mertz Taggart’s judgment, not a guarantee of transaction outcomes.

  • 2027 Home Health Final Rule: What It Means for Agency Values and M&A

    By Cory Mertz, M&AMI, Managing Partner, Mertz Taggart | November 6, 2026 The 2027 home health final rule is modestly positive for M&A involving established, compliant agencies. It gives buyers a clearer near-term reimbursement picture, but it does not automatically increase what your agency is worth. Stronger enrollment enforcement also makes ownership history and accurate filings more important to a transaction. Key Takeaways CMS projects a 2.4% (~$415M) aggregate Medicare home health increase for 2027, effective Jan 1. The 3% temporary adjustment is already in 2026 rates, not a new cut on top of the 2.4%. Higher rates can lift EBITDA; they don't by themselves raise multiples. Tighter 36-month-rule enforcement makes ownership history and filings a bigger diligence item. The palliative care clarification adds no new payment stream. CMS issued the final rule on November 4, 2026. For an owner considering a sale, the practical questions are how it affects your earnings, whether your provider agreement can transfer under the contemplated structure, and what a buyer will need to verify. What changed in Medicare home health payments for 2027? CMS estimates that aggregate Medicare home health payments will increase 2.4%, or approximately $415 million, in 2027 compared with 2026. That includes a 2.1% payment update—a 3.1% market-basket increase less a 1.0-percentage-point productivity adjustment—and an estimated 0.3% increase from changes to high-cost outlier payments. Component 2027 Market-basket increase +3.1% Productivity adjustment −1.0 pt Net payment update +2.1% High-cost outlier changes +0.3% Aggregate change vs. 2026 (~$415M) +2.4% The 3% temporary adjustment applies to both 2026 and 2027 payments, so it is not an additional cut to the 2.4% increase. CMS is not applying an additional permanent behavioral adjustment for 2027. However, it retains the ability to make further adjustments, and the temporary-recovery obligation remains. Owners and buyers should not assume that the temporary reduction will simply disappear after 2027. The payment provisions take effect January 1, 2027. The national increase is not a forecast for your agency: geography, patient mix, low-utilization payment adjustments (LUPAs), and outlier utilization can produce a different result. It also does not automatically increase Medicare Advantage, Medicaid, or other payer rates. Will the final rule increase home health agency values? It may support value through improved earnings, but a higher reimbursement rate is not the same thing as a higher valuation multiple. The distinction matters because enterprise value depends on both sustainable adjusted EBITDA and the multiple a buyer will pay for those earnings. A payment increase that reaches the bottom line can increase value even if the multiple stays the same. If higher labor and other expenses absorb that increase, the valuation benefit may be limited. For illustration, assume your agency has $10 million in annual revenue, with 70% from traditional Medicare. If those Medicare payments increased 2.1% at unchanged volume and mix, revenue would rise by approximately $147,000 before expense changes. This is a simplified illustration, not a prediction of your agency’s reimbursement or EBITDA. As we explain in how buyers evaluate home health agency value, the reliability and durability of earnings matter alongside their size. The useful next step is to model the final rates against your actual claims and then assess the cost of delivering that care. What should an owner considering a sale know about enrollment? The final rule strengthens enforcement of the existing 36-month majority-ownership requirements. It does not impose a new blanket restriction on selling a home health agency. A nonexempt change in majority ownership within 36 months of initial enrollment or the most recent majority-ownership change requires new enrollment and a survey or accreditation; the existing provider agreement does not transfer. The final rule adds explicit authority to deny or revoke enrollment for noncompliance with those requirements. CMS also identifies management agreements that effectively transfer control before a later purchase as potential circumvention. Management agreements are not prohibited generally, but their substance matters. You and your transaction counsel should resolve whether the contemplated structure complies before relying on an interim arrangement. The separate nationwide enrollment moratorium announced in May 2026 was imposed for six months and may be extended. Transactions requiring initial enrollment can be affected. An existing provider agreement may make an acquisition more attractive than starting a new agency, but neither transferability nor a permanent scarcity premium should be assumed. Historical enrollment accuracy matters as well. CMS expands retroactive revocation provisions and broadens the affiliations and managing personnel relevant to enrollment oversight. Not every administrative error triggers revocation, but a buyer has more reason to verify ownership filings, management disclosures, and known enrollment issues rather than rely solely on the agency’s current billing status. Does palliative care create a new revenue stream? Not under this rule. CMS clarifies that qualifying skilled palliative care can be furnished within the existing home health benefit. It does not create a separate benefit, payment add-on, or dedicated billing code, and existing home health eligibility requirements still apply. That clarification may support how an agency serves seriously ill patients and works with referral partners. It is not, by itself, a basis for adding a new reimbursement stream to a sale forecast. Should the final rule change your decision to sell? Not on its own. Our assessment is that the rule provides useful near-term payment visibility while reinforcing the importance of a well-documented, transferable business. It does not establish that all home health agencies are worth more or that owners need to sell before another policy change. If you are considering a sale, focus on what the rule changes in your agency’s sustainable earnings and transaction readiness. For broader transaction context, see our Q3 2026 Home-Based Care M&A Report. If you would like to discuss how the rule affects your agency’s value or sale plans, contact Mertz Taggart for a confidential conversation. You do not need to be ready to sell to begin that discussion. Frequently asked questions Are Medicare home health payments increasing in 2027? CMS estimates a 2.4% aggregate increase over 2026. Individual agency results will vary with geography, patient mix, and other payment factors. The increase does not automatically apply to other payer contracts. Is the 3% temporary adjustment an additional cut to the 2.4% increase? No. Both 2026 and 2027 payments include a 3% temporary adjustment. CMS’s estimated 2.4% year-over-year increase already accounts for the finalized policies. Does the 2027 final rule change the home health 36-month rule? It strengthens enforcement of the existing majority-ownership requirements through explicit denial and revocation grounds. Whether a sale requires new enrollment depends on the ownership history, transaction structure, and applicable exceptions. Will the rule increase my home health agency’s valuation multiple? Not automatically. A reimbursement increase may support sustainable earnings, but the rule alone does not establish a higher multiple. Agency-specific performance, risk, and buyer interest still need to be assessed. Cory Mertz, M&AMI, is Managing Partner at Mertz Taggart, where he advises home health, home care, and hospice owners on selling their businesses. This article reflects the final rule released November 4, 2026, and information available November 5, 2026. It provides general M&A commentary, not legal advice.

  • The Resurgence of Private Duty Home Care M&A

    By Cory Mertz, Managing Partner, Mertz Taggart At a Glance Private duty home care M&A is picking up after a quiet two years. Buyer interest is returning, platforms are receiving new capital, and the regulatory environment around government-funded care is pushing some acquirers toward private-pay alternatives. For owners of non-medical home care agencies funded by private pay or LTC insurance, the market is more receptive than it has been in some time. The fundamentals still drive outcomes, but a broader buyer pool gives sellers more options on price, structure, and what comes next. Private duty home care M&A is beginning a resurgence. Over the past three months, we have heard from more buyers asking about private duty home care opportunities—or making sure we still have them on our radar—than we did in the previous two years. Some are new to us. Others are established buyers renewing their interest. That is a meaningful change in the conversations we are having. The interest is backed by investment in established platforms and continued acquisitions of local agencies. For owners who have been waiting for a more receptive market, the change is worth paying attention to. Government-funded home-based care transactions have become harder to underwrite and close. Buyers still need to grow, and private duty home care offers a path without direct dependence on government reimbursement. What We Mean by Private Duty Home Care Private duty home care is non-medical care funded by private pay or LTC insurance. It includes companionship, meal preparation, transportation, medication reminders, and assistance with activities of daily living. It does not include Medicaid-funded personal care or VA-funded services. It is also different from private duty nursing, which involves skilled nursing care delivered in the home. A private duty agency has plenty of operating challenges: caregiver recruiting and retention, wage pressure, scheduling, client turnover, and local management. But it does not face the same government rate-setting, enrollment, billing-review, or repayment exposure that buyers must evaluate in Medicare- and Medicaid-funded businesses. That difference is becoming more valuable. Recent Investments Show Where Buyers Are Looking The past 12 months have brought a series of investments in home care platforms—from healthcare-focused sponsors and franchise investors to international operators. Frontline Healthcare Partners acquired Integracare, a Canada-based private-pay home care provider, in October 2025. NexPhase Capital invested in Always Best Care the following month. In January 2026, Main Post Partners acquired HomeWell Care Services. A month later, Dovida entered the U.S. through its acquisition of A Place at Home. General Atlantic’s reported $3 billion acquisition of TEAM Services Group, a diversified home care and household employment platform with private-pay operations. Warburg Pincus also invested in Cornerstone Caregiving, a national non-medical home care provider serving both private duty and VA-funded clients. The acquisitions are happening at the local level, too. Avenues Home Care acquired Alabama-based As Close As Family in October 2025, an example of the expansion these platforms are pursuing. Some of these platforms operate across multiple payer or service lines. The common thread is investment in home care businesses with private duty exposure, not an exclusive focus on private-pay providers. For an agency owner, the significance goes beyond the announcements. A platform investment puts capital, management resources, and acquisition capacity behind a business. Your agency may provide the geographic coverage, caregivers, referral relationships, or leadership team that buyer needs next. Government Scrutiny Is Changing the Calculation The private duty investment case predates the current fraud crackdown. But the environment around government-funded healthcare has made the comparison more compelling. In May 2026, CMS imposed nationwide Medicare enrollment moratoria on new home health agencies and hospices, including certain changes in majority ownership. The agency also announced expanded investigations, enrollment screening, site visits, and claims reviews. Medicaid enforcement has intensified as well. CMS reported that the first 88 days of its Medicaid Fraud War Room produced federal or state enforcement activity involving 50 high-risk providers and more than $203 million of Medicaid payments. In a transaction, that environment means more attention to billing practices, eligibility documentation, payer contracts, enrollment history, and potential repayment exposure. Medicaid adds state-specific requirements that can affect transaction structure and closing. We are seeing how difficult it can be to get government-funded deals across the finish line, even when the underlying business is attractive. Buyers with both government-funded and private duty operations have a choice about where to deploy acquisition capital. Private duty allows them to add clients, caregivers, referral relationships, and cash flow without taking on the same reimbursement uncertainty. What Buyers See in Your Agency For owners of private duty platforms, the expanding buyer universe is particularly significant. Buyers looking to enter the sector or establish a regional presence will pay a premium for a business that already has the management team, operating infrastructure, and scale to support further growth. They are acquiring both current earnings and the ability to build on them. Established local agencies can also benefit. A buyer may value your agency for its market position, caregiver base, referral relationships, or the density it adds to an existing footprint. The value depends on what you have built—and what it allows the buyer to do next. That is why the buyer’s strategy matters as much as the headline multiple. A competitive process helps identify who sees the greatest value in your business and gives them a reason to pay for it. Nova Leap Provides a Public-Market Perspective Nova Leap Health is a Canadian company headquartered in Halifax, trading on the TSX Venture Exchange under NLH and on the U.S. OTCQX market under NVLPF. It has built much of its U.S. home care business through acquisitions, with U.S. operations accounting for approximately three-quarters of revenue in the first half of 2026. In our view, Nova Leap is the closest public-market comparable for private duty home care. Its focus on acquiring and operating local home care agencies makes it particularly relevant to owners considering a sale. The company’s share price increased approximately 82% between year-end 2025 and September 30, 2026. It also reported record Q2 results, with revenue increasing 17.1% and Adjusted EBITDA increasing 65.2% from the prior-year quarter. As of September 30, Nova Leap had an enterprise value of approximately US$34.3 million, representing roughly 13.2x its US$2.6 million of trailing-12-month Adjusted EBITDA through June 30, 2026. What This Means if You Are Considering a Sale A broader buyer market can give you more choices—not just on price, but on your role after closing, the future of your team, and how the business continues to grow. The fundamentals still determine the outcome. Buyers want reliable financials, defensible margins, stable client relationships, and a business that can operate after the owner steps away. Those qualities become more valuable when several credible buyers are competing for them. If you have thought about selling but assumed the market was too quiet, this is a good time to revisit that assumption. The freeze is beginning to thaw. We are hearing directly from buyers, investors are committing capital, and platforms are expanding. If you own a private duty home care agency, and are curious about how it would be viewed in the current private duty M&A marketplace, we’ll be happy to have a discussion. Key Takeaways Buyer interest in private duty home care has increased noticeably over the past three months, after a relatively inactive two-year period. Recent investments by sponsors including NexPhase Capital, Main Post Partners, and General Atlantic reflect a broader capital commitment to home care platforms with private-pay exposure. Government enforcement activity, including CMS moratoria on new Medicare home health and hospice enrollments and expanded Medicaid fraud investigations, is making government-funded deals more complex to underwrite and close. Private duty home care avoids the reimbursement rate-setting, billing review, and repayment exposure that buyers must evaluate in Medicare- and Medicaid-funded businesses, which is part of what makes it more attractive now. Nova Leap Health, a public-market comparable for private duty home care, saw its share price increase approximately 82% between year-end 2025 and September 30, 2026, alongside record Q2 revenue and EBITDA results. Buyers are looking for agencies with reliable financials, defensible margins, stable client relationships, and operational infrastructure that can support growth after the owner exits. A competitive sale process helps identify which buyers place the highest value on a specific agency and gives them a reason to pay for it. The Q3 2026 Home-Based Care M&A Report is now available.

  • Q1 2026 Home-Based Care M&A Report

    Home-based care M&A activity held steady in Q1 2026, with 22 transactions closed during the quarter — continuing the momentum from last year's rebound. Seven additional deals were announced but not yet closed as of quarter-end, signaling a healthy pipeline heading into the second quarter. Hospice led all sub-sectors with 10 closed transactions, followed by home care at 9 and home health at 6. Q3 2026 Home-Based Care M&A Report is now available. Cory Mertz, managing partner at Mertz Taggart, noted: "Q1 2026 was an encouraging start to the year. We're seeing more sponsors reach the point where they need to transact — some of these platforms have been held for five, six, seven years, and the pressure to return capital to LPs is real. The clock is ticking on a lot of these funds, and buyers are active. We expect deal volume to continue building through Q2 and into the back half of the year." Home-Based Care M&A Note: Total industry transactions do not necessarily equal the sum of the sub-industries, as many transactions include more than one sub-industry. The 22 closed transactions in Q1 2026 were driven by sponsor-backed activity across all three sub-sectors. Home care and hospice each contributed double-digit deal counts on a combined basis, while home health showed modest improvement from the multi-quarter lows seen through much of 2024 and early 2025. Cory Mertz added: "The announced deals this quarter tell the real story. Elara Caring, Enhabit, TEAM Services, Aveanna/Family First — these are meaningful transactions that reflect growing conviction from both buyers and sellers." Home Health M&A Home health activity improved in Q1 2026, with 6 total transactions — including 1 new platform and 5 sponsor-backed add-ons — up from 3 in Q4 2025 and the best quarter for the sub-sector in over a year. The quarter's headline deal was the announced acquisition of Enhabit Home Health & Hospice by Kinderhook Industries for $1.1 billion, representing a 10.2x EBITDA multiple on $108 million of EBITDA and $1.06 billion in revenue. Enhabit had been publicly traded since spinning out of Encompass Health in 2022 and had spent much of its time as a standalone company navigating reimbursement headwinds and investor skepticism about Medicare home health. The Kinderhook deal delivers a 24% premium to Enhabit's share price at announcement and nearly 34% to the 60-day average — the kind of outcome that speaks for itself. Cory Mertz offered this perspective: "The Enhabit deal is a good reminder of why we don't lead with multiples. Shareholders received a 24% premium to market and nearly 34% to the 60-day average — real value by any measure. But if you just read '10.2x EBITDA' in a headline, it sounds unremarkable. The multiple is an output, not the goal. For Enhabit's board, the goal was maximizing value for shareholders and getting the company out from under the quarterly earnings spotlight — both of which this transaction accomplished." Also announced — but not yet closed — was Ares Management's (alongside DaVita) strategic investment in Elara Caring, the large national home health, hospice and personal care platform formed in 2018 from the three-way merger of Great Lakes Caring, National Home Health Care and Jordan Health Services. Blue Wolf Capital had held the asset for nearly eight years — an unusually long hold period by private equity standards — navigating a difficult regulatory environment, a $4.2 million DOJ settlement in 2024, and a home health reimbursement landscape that kept many large-platform exits on hold. DaVita disclosed an approximately $200 million minority investment alongside a majority investment from Ares, with Elara continuing to operate as an independent company. The strategic rationale centers on co-developing a kidney-specific in-home care model, leveraging DaVita's clinical expertise to reduce preventable hospitalizations and lower total cost of care for patients with kidney disease. Among closed deals, Choice Health at Home added Cyfair Healthcare in Texas and Alliant Home Health in back-to-back transactions, extending its multi-state footprint. Residential Healthcare Group acquired Covenant Home Health to deepen its presence in eastern Pennsylvania, and Superior Health Holdings closed on Pulse Home Health & Hospice. Also announced was Aveanna Healthcare's agreement to acquire Family First Homecare for $175.5 million. Family First is a pediatric home care provider focused on skilled private duty nursing, operating 27 locations across seven states including Florida and Texas. The deal expands Aveanna's specialized pediatric footprint and reinforces its strategy of building scale in medically complex, high-cost patient populations. Hospice M&A Hospice maintained its position as the most active sub-sector in Q1 2026, with 10 closed transactions — including 5 sponsor-backed strategic add-ons. This is consistent with the record activity seen in Q4 2025 and confirms hospice as the preferred target for both strategic and financial buyers in the current environment. Notable transactions include Uplift Hospice's purchase of Autumn View Hospice in Georgia, continuing the platform's active acquisition streak. On the not-for-profit side, Chapters Health System announced another transaction in its acquisition of HouseCall Providers, a Portland, Oregon-based organization offering home health, hospice and palliative care services across the Pacific Northwest. Hospice of Southern Maine announced the pending acquisition of Andwell Health Partners, and VNA of Texas completed the acquisition of Faith Presbyterian Hospice. Heart to Heart Hospice continued its add-on pace with the acquisition of a former Cura-HPC location in Oklahoma City. Kara Health launched a joint venture with Loma Linda University Health to form Loma Linda University Hospice, expanding Kara's health system partnership model into the Inland Empire region of California. Cory Mertz noted: "Hospice M&A has been on a run, and we don't think it's over. The activity we saw in Q4 2025 and Q1 2026 is being driven by real demand from buyers and growing willingness from owners to engage. A few precedent platform transactions were received well in 2025, and that fuels more PE interest in the space — which drives demand for all hospice agencies, large and small. For hospice operators who are thinking about a sale in the next one to three years, the current environment rewards preparation — particularly around billing compliance and documentation." Home Care M&A Non-medical home care contributed 9 closed transactions in Q1 2026, including 5 sponsor-backed strategic add-ons and 1 new platform. While slightly below the elevated levels seen in Q1 and Q2 2025, activity remained healthy and the announced deal pipeline points to continued momentum. The quarter's most notable announced transaction was General Atlantic's acquisition of TEAM Services Group, one of the largest Medicaid-focused home and community-based services providers in the country, from Alpine Investors, which had built the platform through more than a decade of aggressive add-on activity since forming the company in 2015. The deal, backed by $1.38 billion in financing, closed in early Q2 — but its announcement during the quarter is a meaningful signal of continued large-platform appetite in the home care space. Among closed deals, Care Advantage acquired the Delaware locations of Neighborly Home Care, HouseWorks HomeCare added A Caring Experience Nursing Services in the Northeast, and PurposeCare added Freedom Home Care to its expanding portfolio. Choice Health at Home continued its aggressive add-on pace, closing on Florida-based Senior Nannies Home Care Services in addition to its home health transactions this quarter. Q1 also saw two home care franchise networks change hands: Main Post Partners established a new platform with the acquisition of HomeWell Franchising, and Dovida, a global home care provider operating across six international markets, made its U.S. market entry with the acquisition of A Place At Home, a franchise network with approximately 55 locations across 27 states. Cory Mertz noted: "Home care is still very much in play. We have a number of sponsor-backed platforms that have been building for several years and are getting close to exit-ready, and buyers — including some we haven't seen active in a while — are showing renewed interest." If you are interested, you can also download the .PDF version of the Q1 2026 Home-Based Care M&A Report via the following link:

  • Q2 2026 Home-Based Care M&A Report

    By Cory Mertz, M&AMI, Managing Partner, Mertz Taggart Published July 21, 2026. Transaction data reflects deals closed between April 1 and June 30, 2026, as tracked by Mertz Taggart - Q3 2026 Home-Based Care M&A Report is now available At a Glance Home-based care M&A volume stepped down in Q2 2026, with 16 transactions closed during the quarter — down from 27 in Q1 2026 and 29 in Q2 2025. Hospice and home care tied for the lead at 8 closed transactions each, followed by skilled home health at 6. Deal count cooled, but dollar volume did not: General Atlantic's approximately $3 billion acquisition of TEAM Services Group and Kinderhook Industries' $1.1 billion take-private of Enhabit both rank among the largest home-based care transactions on record. New platform formation outpaced add-ons for the first time in years. Home-Based Care M&A Activity in Q2 2026 Home-based care M&A volume stepped down in Q2 2026, with 16 transactions closed during the quarter — down from 27 in Q1 2026 and 29 in Q2 2025. Hospice and home care tied for the lead at 8 closed transactions each, followed by skilled Home Health at 6. Two additional deals were announced but not yet closed as of quarter-end. Two of the quarter’s closings ranked among the largest home-based care transactions on record: General Atlantic’s approximately $3 billion acquisition of TEAM Services Group and Kinderhook Industries’ $1.1 billion take-private of Enhabit. Together they underscore that, even as deal count cooled, large-cap sponsor capital remained firmly committed to scaled home-based care platforms. Cory Mertz, managing partner at Mertz Taggart, noted: “The count came down this quarter, and it’s fair to ask whether the regulatory environment is part of it — the fraud takedowns, the hospice 36-month rule, the new enrollment moratorium and enhanced oversight all make deals more complex to get across the line. But it’s one quarter, and the dollars tell the other side of the story. Sponsors are still writing big checks and, increasingly, looking to return capital to LPs after long hold periods.” How the quarter broke down by buyer type By structure, the quarter comprised six new PE platform investments, four sponsor-backed strategic add-ons, one public-company acquisition, and five post-acute, or independent buyers. New-platform activity outpaced add-ons — a reversal of the add-on-heavy pattern of recent years — as several sponsors established fresh platforms in the sector. Note: Total industry transactions do not necessarily equal the sum of the sub-industries, as many transactions include more than one sub-industry. → Related: Selling a Home Health, Hospice, or Home Care Agency in 2026 Home Health M&A in Q2 2026 Home health saw 6 closed transactions — including two new platform investments, one sponsor-backed add-on, and three other strategic or independent buyers — down from 8 in each of the prior two quarters. Kinderhook Industries completes its take-private of Enhabit The quarter’s headline deal was Kinderhook Industries’ completed take-private of Enhabit, the home health and hospice provider that spun out of Encompass Health in 2022 and spent much of its time as a publicly traded company navigating Medicare home health reimbursement headwinds and investor skepticism. Enhabit shareholders received $13.80 per share in cash — a total enterprise value of roughly $1.1 billion (equity plus roughly $480 million of assumed debt), representing a 10.2x EBITDA multiple on $108 million of EBITDA, a 24% premium to the undisturbed share price and nearly 34% to the 60-day average. Cory Mertz offered this perspective: “The Enhabit deal is a good reminder of why we don’t lead with multiples. Enhabit shareholders received a 10.2x EBITDA, which sounds unremarkable for a billion-dollar, public company. But this was a 24% premium to market and nearly 34% to the 60-day average — significant by any measure.” Other closed home health transactions Among other closings, PruittHealth acquired Georgia Home Health Services, extending its home health presence in South Georgia; Lucent Home Health acquired Chambers Home Health Agency of Northeast Texas, a combined home health and hospice operation; and Renovus Capital Partners-backed Superior Health Holdings added Chant Healthcare, entering Oklahoma across home care, home health and hospice. Heritage Home Health and Hospice and Legacy Hospice formed an Ohio joint venture. Hospice M&A in Q2 2026 Hospice matched home care at 8 closed transactions — three platform investments, two sponsor-backed add-ons, and three strategic or independent buyers — extending the steady, add-on-heavy consolidation that has defined the segment. Webster Equity Partners-backed Bristol Hospice acquired Hope Hospice & Palliative Care, while Norwest made a platform investment in Ennoble Care, a home-based care provider spanning home care and hospice. 5th Century Partners invested in Capstone Hospice, establishing a new platform, and Stillwater Hospice agreed to take over the hospice operations of Campbell County Memorial Hospital. Home Care M&A Non-medical home care tied for the lead at 8 closed transactions — three platform investments, three sponsor-backed add-ons, one public-company deal, and one independent buyer — powered by the quarter’s largest transaction. General Atlantic acquires TEAM Services Group in the quarter's largest deal General Atlantic acquired TEAM Services Group, a San Diego-based, scaled home-based care services company, from Alpine Investors for a reported purchase price of approximately $3 billion — one of the largest home-based care transactions on record. TEAM’s EBITDA was reported, but the transaction’s EBITDA multiple can’t be reliably calculated: only the purchase price is known, not enterprise value. Other closed home care transactions Elsewhere, Warburg Pincus made a platform investment in non-medical home care provider Cornerstone Caregiving, with financing from Monroe Capital; Addus HomeCare acquired HomeCourt Home Care, marking its entry into Indiana; Searchlight Capital Partners-backed Care Advantage added First Priority Home Care; SIG Partners-backed Pillar Health Group acquired Krista Care; and Feature Healthcare acquired Carepoint. Deacon Associates to acquire 31 agencies from HCA Healthcare One of the quarter's most significant announced (but not yet closed) transactions was Deacon Associates' agreement to acquire 31 home health and hospice agencies from HCA Healthcare (NYSE: HCA) , with terms undisclosed. The divested assets span eight states and will be folded into Central Pyramid, a Deacon subsidiary; the portfolio includes agencies HCA had picked up through its 2021 acquisition of an 80% stake in Brookdale Senior Living's health care services segment. The deal is expected to close in roughly three months, pending regulatory approval. It stands out as a large health system stepping back from home-based care even as operators like Deacon — in CEO Trey Crabb's words — "double down on home health and hospice." Cory Mertz added: “For owners weighing a process over the next 12 to 24 months, this environment rewards preparation. Diligence around billing and compliance has only intensified — especially in the enhanced-oversight states — and the sellers who invest early in getting their house in order are the ones who hold their value all the way through to close.” Key Takeaways 16 home-based care transactions closed in Q2 2026, down from 27 in Q1 2026 and 29 in Q2 2025. Hospice and home care tied at 8 closed transactions each; home health closed 6. Deal count fell but dollar volume did not — two of the largest home-based care transactions on record closed during the quarter. General Atlantic acquired TEAM Services Group from Alpine Investors for a reported ~$3 billion, the quarter's largest transaction. Kinderhook Industries took Enhabit private at roughly $1.1 billion enterprise value, a 10.2x EBITDA multiple representing a 24% premium to the undisturbed share price. New platform formation (6 deals) outpaced sponsor-backed add-ons (4), reversing the add-on-heavy pattern of recent years. Regulatory pressure — fraud takedowns, the hospice 36-month rule, the enrollment moratorium, and enhanced oversight — is making deals more complex to close. Deacon Associates agreed to acquire 31 home health and hospice agencies from HCA Healthcare, a large health system stepping back from home-based care. For owners planning a process in the next 12 to 24 months, billing and compliance diligence has intensified, and early preparation is what protects value through to close. If you are interested, you can also download the .PDF version of the Q2 2026 Home-Based Care M&A Report via the following link:

  • Q3 2026 Behavioral Health M&A Report

    By Kevin Taggart, CM&AP, Managing Partner, Mertz Taggart Published November 2026. Transaction data reflects deals closed between July 1 and September 30, 2026, as tracked by Mertz Taggart. Behavioral Health M&A At a Glance Behavioral health M&A picked up in Q3 2026, led by mental health and Universal Health Services' $835 million Talkspace closing, with sponsor-backed platforms accounting for half of traditional volume. A total of 33 closed transactions — 28 traditional M&A deals and 5 growth deals — were reported in Q3 2026. Traditional M&A volume rose from 23 closed deals in Q2 2026, though it remained below the 36 closed in Q3 2025. The five growth deals carried a combined disclosed value of approximately $73.4 million. "This was a better quarter, not a breakout one, but definitely a great way to go into the 4th quarter. Volume came back off a light second quarter, and the mix tells you where the confidence is: sponsor-backed platforms doing add-ons, a public company closing a large virtual care deal, and one of the best-known consumer brands in mental health agreeing to sell," Mertz Taggart Managing Partner Kevin Taggart said. Note: Total industry transactions do not necessarily equal the sum of the sub-industries, as many transactions include more than one sub-industry. Sponsor-backed strategics drove the quarter. Fourteen of the 28 traditional deals were add-ons by private equity- or venture-backed platforms, up from 9 in Q2 2026, led by Latticework Capital-backed Beacon Behavioral Partners with four outpatient psychiatry deals. The policy backdrop remained a factor. CMS proposed in July to limit the provider taxes states use to fund their share of Medicaid, and Medicaid work requirements take effect January 1, 2027. On the other side of the ledger, Medicare telehealth flexibilities now run through December 31, 2027, giving virtual mental health providers a longer runway. "Medicaid is still the variable everyone is underwriting, and buyers will stay careful on Medicaid-heavy businesses at least until after the mid-term elections. But careful isn't absent. We're seeing genuine buyer interest in Medicaid providers in our own pipeline for well-run, compliant outpatient and community-based providers." Addiction Treatment M&A Eight addiction treatment deals closed in Q3 2026, up from 2 in Q2 2026 and down from 10 in Q3 2025. Two of the larger closings involved distressed sellers, and nonprofit combinations accounted for much of the rest. Spero Health doubles its footprint with CleanSlate The most significant addiction treatment transaction was Heritage Group-backed Spero Health's acquisition of CleanSlate Centers, a multi-state office-based opioid treatment provider, which closed July 1. The combined company operates 128 locations across 10 states, roughly doubling Spero's footprint. Spero took CleanSlate's equity in exchange for assuming its debt and paying deal expenses; public filings described the deal as necessary to prevent CleanSlate's closure. Other closed addiction treatment transactions: Advanced Recovery Systems acquired Promises Behavioral Health in early July, creating a combined operator of 24 facilities in 14 states offering detox, inpatient, residential and outpatient care. Renew Health + Recovery, led by Aware's chief executive, purchased substantially all of the assets of in-home treatment provider Aware Recovery Care in September, continuing service across the same 11 states. Ignitus Recovery acquired AIM House. Family & Children's Services and HOPE Community Services completed their merger in Oklahoma, forming a $208 million behavioral health system with nearly 1,800 employees; The Village for Families & Children combined with Wellmore's Liberty Center outpatient program in Connecticut; and River Edge Behavioral Health merged with Oconee Center in Georgia. Mental Health M&A Twenty-four mental health deals closed in Q3 2026, up from 16 in both Q2 2026 and Q3 2025 and the sub-sector's highest total since Q1 2025. Outpatient psychiatry add-ons and virtual care consolidation drove the count. UHS completes its $835 million acquisition of Talkspace The largest transaction of the quarter in any sub-sector was Universal Health Services' (NYSE: UHS) completion of its approximately $835 million acquisition of Talkspace (NASDAQ: TALK) on August 17. Talkspace's network of about 6,000 licensed providers is available to more than 200 million people through health plans, employers and other channels, and now links to UHS' behavioral hospitals and outpatient locations. "We're at an inflection point in how mental healthcare is delivered," said Marc D. Miller, President and CEO of UHS. "... The addition of Talkspace expands our ability to connect people with care when, where and how they need it most." Oceans Healthcare adds a New Orleans campus Webster Equity Partners-backed Oceans Healthcare acquired Perimeter Behavioral Hospital of New Orleans, now Oceans' Kenner West campus, providing adult and older adult inpatient care plus outpatient programming. Mertz Taggart provided advisory services in this transaction. Other closed mental health transactions: HCA Healthcare sold Dominion Hospital, a behavioral health hospital in Falls Church, Virginia, to Hill Valley Healthcare, historically a skilled nursing and senior living operator, for $25 million. Beacon Behavioral Partners partnered with Pure Psychiatry (Michigan and Ohio) and AR Psychiatric & Counseling Center (its first Georgia deal) and acquired Prime Psychiatry and Invicta Healthcare in Texas. Health Catalyst Capital formed a new platform with the acquisition of a Midwest psychiatric care provider, and Seven Hills Capital acquired a company to be named in the coming months. Mindoula Health acquired Valera Health and Janus Healthcare Partners; General Catalyst-backed Radial acquired Mindful Health Solutions; and XRHealth acquired Swing Therapeutics. New Harbor Capital-backed Bloom Health Centers acquired Baltimore-based Insight Physicians, Collaborative Health Partners acquired Advanced Psychotherapeutics, and Devereux acquired Gigi's House. Mental health growth capital in Q3 2026 Mental health accounted for four of the quarter's five growth rounds. Flourish Health raised $26 million in a Series A led by B Capital, F-Prime and Cherryrock Capital to expand its in-home, psychiatrist-led care for high-acuity youth. Handspring Health raised $19 million from investors including RPS Ventures; Onos Health raised $17 million from Costanoa, Flare Capital and CVS Health Ventures; and Overstory Health raised $1.4 million. "Mental health is where the market's confidence showed up this quarter — a public hospital company closing on a virtual platform, and sponsor-backed psychiatry groups adding practices every few weeks. Outpatient psychiatry with good payer contracts remains one of the most sought-after assets we see," Taggart said. Autism and Intellectual/Developmental Disabilities M&A Six autism and I/DD deals closed in Q3 2026, compared with 7 in Q2 2026 and 10 in Q3 2025. Nonprofit and independent buyers accounted for four of the six, alongside two sponsor-backed pediatric add-ons. Closed autism and I/DD transactions: Thurston Group-backed Arc Health partnered with The Waverly Group to expand collaborative pediatric care in Connecticut. Leavitt Equity Partners-backed Pediatrics Plus acquired AR Kids Pediatric Day Centers in Arkansas. Nonprofit and independent combinations included Ann Storck Center's acquisition of Victory Living Programs in South Florida, Hope Network's acquisition of Developmental Enhancement Behavioral Health, New Jersey-based Infinity Today's move to employee ownership through Indiana Professional Management Group, and the River Edge–Oconee Center merger in Georgia. On the growth side, Prosper Health raised $10 million from investors including Maverick Ventures to support diagnosis and care for adults with autism. Announced Transactions (Not Yet Closed) These transactions had not closed as of September 30 and are excluded from the quarter's counts and charts. Sword Health agrees to acquire Headspace General Catalyst-backed Sword Health agreed on September 16 to acquire Headspace, whose app is offered by more than 20,000 employers, in an all-cash deal reported to be valued near $300 million. The deal brings Headspace's brand, enterprise distribution and network of more than 15,000 providers into Sword's AI care platform. It closed October 1 and will be reflected in our Q4 2026 count. Other announced transactions: KKR-backed Geode Health agreed to take over Baylor Scott & White's outpatient mental health services in Texas, with the transition scheduled for late October. Chimes and Upper Bay Counseling and Support Services in Maryland announced plans to combine, with closing expected in January 2027. Terra Behavioral Health agreed to acquire Latitude Recovery Center in Carlsbad, California. If you are interested in downloading the PDF version of the Q3 2026 Behavioral Health M&A Report, click the download link below:

  • Q3 2026 Home-Based Care M&A Report

    By Cory Mertz, M&AMI, Managing Partner, Mertz Taggart Home-based care M&A volume stepped down in Q3 2026, with 11 transactions closed during the quarter, down from 23 in Q2 2026 and 22 a year ago. Home health and hospice tied for the lead at six closed transactions each, followed by home care at four. Private equity remained the most active source of capital: eight of the 11 closings were either new sponsor platform investments or add-ons by sponsor-backed strategics. The softer count tracked the broader healthcare market, where LevinPro's preliminary data showed announced deal volume down 16% from Q2. Several significant deals were announced but not closed by quarter-end, led by Addus HomeCare's agreement to acquire AccentCare's personal care division for approximately $275 million; those are covered below and excluded from the count. “Q3 was a light quarter, but it is one quarter—not a trend. Deals are taking longer to close, and we fully expect a strong Q4,” said Cory Mertz, managing partner at Mertz Taggart. Home-Based Care M&A Note: Total industry transactions do not necessarily equal the sum of the sub-industries, as many transactions include more than one sub-industry. Of the 11 closings, six were add-ons by sponsor-backed strategics, two were new sponsor platform investments, one was by a strategic buyer, and two were by other buyers, including independent operators. The quarter played out against an active regulatory calendar. In May, CMS announced a six-month nationwide moratorium on new home health and hospice enrollments. In July, CMS issued its proposed CY 2027 home health rule, which it estimates would increase aggregate Medicare home health payments by 2.4% while expanding program-integrity and enforcement provisions. For hospice, the FY 2027 final rule set a 2.3% payment update, effective October 1, 2026. “Buyers have gotten more careful, and that's not bad news for owners who run a clean shop. Compliance history, documentation, and leadership depth are getting a harder look in diligence than they did a few years ago. With positive rate updates on the table for both home health and hospice next year, buyers have a clearer reimbursement picture to underwrite. Agencies that can show they're well run are still getting deals done,” Mertz said. Home Health M&A Home health recorded six closed transactions in Q3 2026: one platform investment, four sponsor-backed add-ons, and one transaction by an independent buyer. The quarter's headline closing was Ares Management's investment in Elara Caring. Ares' Private Equity Group, alongside DaVita as a minority investor, completed its strategic investment in Elara effective July 20, 2026. Elara is a national provider of skilled home health, hospice, behavioral health, and personal care services. Terms were not disclosed, although DaVita reported a cash payment of approximately $200 million at closing for its noncontrolling interest. DaVita and Elara plan to co-develop a kidney-specific home-based care model. Backed by The Vistria Group, VitalCaring acquired Carter Healthcare, adding home health and hospice operations in Ohio and West Virginia and strengthening its presence in Oklahoma, Texas, Kansas, and Missouri. Following the deal, VitalCaring operates 89 home health locations and 40 hospice and palliative care locations. “The Elara closing tells you serious capital still sees home health as a place to build, especially for higher-acuity patients who need to be managed at home. Buyers will pay for scale and clinical capability, and they're willing to wait for the right asset,” Mertz said. Other home health closings included LiveWell Partners' acquisition of Michigan Community VNA Home Health and Hospice, its third acquisition in Michigan; the Detroit-area agency will keep its name and leadership. Webster Equity Partners-backed Care Options for Kids added Health Force, a pediatric home care provider in Chicago. Havencrest Capital Management-backed Avid Health at Home acquired Tech Medical Home Care Services, a home health and personal care provider, entering Kentucky and Ohio with its eighth acquisition. RN Enterprises acquired Helping Hands Home Healthcare in Florida. Hospice M&A Hospice also recorded six closed transactions, matching the prior-year quarter: two platform investments, two sponsor-backed add-ons, one strategic acquisition, and one transaction by an independent operator. “Demand for hospice businesses remains very strong, and there are plenty of deals working toward closing,” Mertz said. Chapters Health System, the largest nonprofit hospice provider in the country, finalized its affiliation with Housecall Providers of Portland, Oregon, in August. The deal expands Chapters' Oregon footprint and adds Housecall's in-home primary care, palliative care, and hospice services to support its value-based care strategy. A healthcare focused private equity group closed on a hospice platform in the western U.S. Family Hospice acquired North Georgia Community Hospice in Dalton, Georgia. The Elara, Carter Healthcare, and Michigan Community VNA transactions also included hospice operations. Home Care M&A Home care recorded four closed transactions: one platform investment and three sponsor-backed add-ons. Flexpoint Ford-backed MGA Homecare acquired the private duty nursing division of Care IV Home Health in Arkansas, expanding its care for medically complex patients. Webster Equity Partners-backed Honor Health Network added Atlanta-based Agility Home Care. The Elara and Tech Medical transactions also included personal care operations. “The Addus announcement is a reminder that buyers are still willing to commit substantial capital to home care. I wouldn’t read one quarter’s closing volume as a lack of demand,” Mertz said. Announced (Pipeline) The following transactions were announced but had not closed as of September 30, 2026. They are not included in the quarter's transaction count, the sub-sector counts, or the charts above. Addus HomeCare (Nasdaq: ADUS) agreed to acquire the personal care division of AccentCare, outside of New York, for approximately $275 million in cash. The business serves an average daily census of about 13,700 clients across 10 states, led by Texas, Illinois, California, and Arizona, and is expected to add approximately $280 million in annualized revenue, roughly 19% of Addus' revenue base. AccentCare's home health and hospice operations are excluded. Dirk Allison, chairman and CEO of Addus, said, "This acquisition continues our growth strategy to leverage our strong personal care experience to build scale in existing markets as well as enter select new markets." Circle of Life agreed to acquire Washington Regional Hospice in Northwest Arkansas, including the Willard Walker Hospice Home, with closing targeted for the end of September. In addition, Center for Hope Hospice and Palliative Care and VNA Hospice NWI announced a strategic affiliation in Indiana. After quarter-end, Deaconess Associations (DAI) closed its acquisition of 31 home health and hospice agencies from HCA Healthcare (NYSE: HCA), comprising 24 home health and seven hospice locations across eight states. The deal, announced in June, places the agencies under DAI's Central Pyramid subsidiary. DAI CEO Trey Crabb said, "I think we were in a unique place to be able to execute the transaction after HCA made the decision to strategically exit the (home health and hospice) business in most of its markets." If you are interested, you can also download the .PDF version of the Q3 2026 Home-Based Care M&A Report via the following link:

  • What Buyers Want to See in Behavioral Health Leadership Teams

    By Kevin Taggart, CM&AP, Managing Partner, Mertz Taggart At a Glance Buyers evaluating a behavioral health leadership team want evidence that the business can operate through an ownership transition. They examine who makes decisions, who is accountable for finance and compliance, and whether key people intend to remain. The structure should fit the business’s size and care model, with responsibilities demonstrated in day-to-day work. A buyer evaluating your behavioral health business will want to understand how much of the operation depends on you, and the answer shapes how they assess the transition they are taking on. That question is worth working through before a sale process starts, particularly if you plan to step back afterward. There is no single organizational chart that solves this for every practice. The useful starting point is the work itself: who is doing it, who has authority to make decisions, and where the operation still needs more support. Look at the decisions that reach your desk One way to assess founder dependence is to look at your own day. Which decisions genuinely need your involvement? Which ones come to you because responsibility has never been assigned elsewhere, or because the team is used to checking with you first? That review can reveal where management capacity needs to develop. Buyers will ask about those same responsibilities. They want to understand how the business handles operating questions, how performance is reviewed, and who follows through when something needs attention. A capable second-in-command can make a meaningful difference, especially when that person already leads substantial parts of the operation. Give people the authority and support to carry their responsibilities, then allow time to see how the arrangement works. If you plan to reduce your involvement, the business benefits from making that change deliberately. You also gain experience you can draw on when a buyer asks how the company would operate after you step back. Use the organizational chart to explain those working relationships, including where responsibilities overlap or still depend on you. → Related: How to Prepare Your Behavioral Health Business for Sale in 2026 Match leadership investment to the business It can be difficult for a smaller behavioral health business to support a full executive team. Buyers understand that. Before adding a senior role, look at the responsibility that needs to be covered and whether the business can sustain the cost. Financial management is a good example. You need reliable reporting and someone who can explain the numbers. A controller may provide that capability at the company's current size. As the business becomes larger or more complex, its needs may justify a CFO. That decision should reflect the complexity of the work and what the business can afford. As the organization grows, business development or corporate development roles may help it expand into new locations or pursue acquisitions. Consider whether someone needs to take responsibility for that work, how the role would change your own involvement, and whether the business can support the investment. Clinical and operating leadership need to fit the care model as well. A structure that works for one behavioral health provider may leave gaps in another. Work through the functions your business depends on, identify who is accountable, and assess where that person needs help. This produces a more useful plan than trying to copy the management team of a much larger company. Give compliance the attention it requires Compliance needs a clear place in the management structure. Before adding another executive title, establish who oversees clinical documentation and billing, who receives concerns, and who has authority to act. That person also needs access to the appropriate expertise, and you should be prepared to explain how management follows through when an issue is identified, with records that support the account. Address retention and the owner's future role A leadership team is most valuable to a buyer when the people the business relies on are available to continue doing the work, and turnover gets attention accordingly. If retention has been difficult, understand the reasons and be prepared to explain how management has responded. Compensation, workload, and employee satisfaction may all be relevant. So are the effects on hiring costs and the practice's ability to maintain its operation. A buyer will learn more from an accurate account of those issues than from a general statement that the company has a strong culture. The intentions of key leaders also matter, but discussing a potential sale with employees requires care. Work with your advisor on whom to involve and when. Confidentiality and the buyer's need to understand leadership continuity have to be managed together throughout the process. Be equally clear about your own plans. If you want to leave after a transition period and a buyer expects you to lead the business for several years, that needs to come out before you select its offer. Your future role is part of the transaction you are negotiating. Key Takeaways Know which decisions already reach the team without you, and be prepared to demonstrate that. Match leadership investment to the complexity and scale of the business, not to what a larger organization would carry. Give financial reporting and compliance a named owner with a documented track record. Resolve your own post-sale role before you select an offer, not after. Building management depth takes time because people need the chance to lead before anyone can evaluate the result. If a sale is on your horizon, look at the responsibilities you would want the team to carry without you and begin there. I’d be glad to talk through it, confidentially. → Related: Selling the Practice You Built

  • Preparing Behavioral Health Financials for a Quality of Earnings Review

    By Kevin Taggart, CM&AP, Managing Partner, Mertz Taggart At a Glance Buyers and quality of earnings firms examine how a behavioral health business earns its money, whether the records support reported earnings, and whether those earnings can continue. Consistent reporting, documented adjustments and operating context make the financial story easier to evaluate. Preparation should begin before buyers rely on the earnings figure in an offer. When a buyer makes an offer, the number behind it depends on your earnings, and a quality of earnings review is how that number gets tested. A firm hired by the buyer examines the earnings, the records supporting them, and how well they reflect the ongoing business. Questions that seemed straightforward while you were running the practice can become more involved when an offer depends on the answer. As an owner, you know the decisions behind your financial results, why staffing costs changed, which expenses were unusual, and what drove a stronger month. Some of that knowledge may live in the financial records; some may live mostly with you and the people who help run the business. Preparing before you are in the middle of a transaction gives your team a stronger basis for the review that follows.The review examines the earnings, the records supporting them, and how well they reflect the ongoing business. Consistent reporting and well-supported explanations give your team a stronger basis for defending the value being negotiated. Make it possible to compare one period with the next Buyers generally want to examine at least two years, plus current YTD of financial results, and sometimes three. They are looking at how the business has changed over time. To do that, they need reporting that lets them compare the same categories across those periods. If an expense appears in one category this year and another category next year, the reviewer has to work out what happened before assessing performance. There may be a perfectly reasonable explanation. Keep it with the records so your accountant and transaction team can answer the question without reconstructing it months later. Someone on your team needs to be responsible for the financial records and available to explain the calculation to your accountant, advisor, and the buyer's reviewers. → Related: How to Prepare Your Behavioral Health Business for Sale in 2026 Be ready to explain each EBITDA adjustment Adjusted EBITDA is intended to reflect the business's normalized earnings before interest, taxes, depreciation, and amortization. The calculation may remove certain owner-related or one-time expenses that are not expected to continue after a sale. Those adjustments, commonly called add-backs, can affect the earnings figure used to negotiate the purchase price. An adjustment needs documentation for both the amount and the reason it belongs in the calculation. What was the expense? When did it occur? Why would removing it give a more accurate view of ongoing earnings? Your accountant and advisor should be able to work through those questions before a buyer's QoE team raises them. If the explanation depends on an assumption about the operation after closing, make that clear. Reviewers may reach different conclusions about an adjustment, and calling a cost nonrecurring will not resolve the discussion on its own. The underlying records and a reasonable explanation are what give your team a basis for the conversation. The same thinking applies when recent earnings have improved. Connect the change to what happened in the business. A staffing decision or an operating improvement may help explain the result, but the buyer still needs to understand whether the benefit can continue. Organizing that documentation early puts you in a better position to address the question. Connect the financials to the way the practice earns revenue The earnings have to make sense alongside the operation. In a behavioral health practice, services are provided, documented, billed, and ultimately paid for. Questions about clinical documentation or billing can therefore become questions about the revenue a buyer is relying on. Revenue that depends heavily on one payer or on grants may need additional support. Explain the concentration, any known collection issue, and the history behind grant revenue, including relationships that depend on the owner. If an audit, licensing concern, or accreditation issue could affect earnings, work with the appropriate specialists and your transaction team to establish the financial implications. Keep the earnings support current The earnings calculation needs to stay connected to the business as the transaction moves forward. Keep current results alongside the periods already presented so your team can explain whether recent performance supports the earnings a buyer is evaluating. If performance changes during the sale process, work with your advisor to explain the difference and provide the relevant records. A change in staffing, costs, or collections may require a fresh look at the earnings calculation. The buyer needs to understand its effect on the ongoing business. Before going to market, review the earnings calculation with your accountant and advisor. Separate adjustments you can already support from those that need more records or depend on an unresolved assumption. That gives the review a clear purpose and shows where more preparation is needed. Key Takeaways Keep financial categories consistent and explain material changes across periods. Document each proposed EBITDA adjustment and the reason it reflects ongoing earnings. Explain payer concentration, grant revenue and known issues that could affect collections. Update the earnings support as current results change during the sale process. If you are considering a sale of your behavioral health business, I’d be glad to talk through where that preparation should begin. → Related: What Actually Happens During Healthcare M&A Due Diligence

bottom of page